ArticleCell2018
Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch.
Open access · bronzeAbstract read
In one paragraph
Article in Cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 321 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
321citing papers in PubMed, 1 pooled it
28.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
321 citing papers in PubMed, 1 synthesis or guideline pooled it, 488 citations in OpenAlex.
- Common and rare variant analyses reveal genetic factors underlying idiopathic pulmonary fibrosis and its shared aetiology with severe COVID-19.EBioMedicine · 2025Pooled it
- Reactivation of the embryonic ζ-globin gene ameliorates severe forms of α-thalassemia.Nature genetics · 2026Article
- Article
- Direct and indirect regulation of fetal globin transcript by the RNA-binding protein IGF2BP1.Blood · 2026Article
- E2F3a transcription factor mediates behavioral, cellular, and DNA-protein regulation of cocaine reward in the nucleus accumbens.Molecular psychiatry · 2026Article
- ERH elicits cell lineage restriction in mammalian preimplantation development and differentiation from pluripotency via H3K9me3-heterochromatin.Nature communications · 2026Article
- New Gene Therapy Strategy for β-Thalassemia.Stem cell reviews and reports · 2026Review
- Review
- Gene Therapy for β-Haemoglobinopathies: From Molecular Correction to Curative Medicine.Biomedicines · 2026Review
- PGC-1α agonism via oral administration of ZLN005 induces fetal hemoglobin and is antisickling in sickle mice.Blood advances · 2026Article
- Dosage compensation defects due to roX RNA loss are rescued by recalibration of X/autosome stoichiometry.Nucleic acids research · 2026Article
- Review
- The NanoBridge system for targeted post-translational modification of challenging proteins.bioRxiv : the preprint server for biology · 2026Article
- A genetic risk score based on BCL11A and HBS1L-MYB variants predicts clinical severity in Brazilian sickle cell anaemia patients.British journal of haematology · 2026Article
- Bipartite DNA binding domain of transcription factor BCL11B binds clustered short DNA sequence motifs.bioRxiv : the preprint server for biology · 2026Article
- COUP-TFII regulates hemoglobin switching by activating the BCL11A-XL repressor LIN28B and directly binding δ and β globin promoters in fetalHaematologica · 2026Article
- Targeted protein degradation for fetal hemoglobin induction: a new paradigm in β-hemoglobinopathy therapy.Biomarker research · 2026Review
- LDB1 represses fetal hemoglobin expression by enhancing BCL11A transcription.Redox biology · 2026Article
- Article
- LSD1 inhibition ameliorates congenital dyserythropoietic anemia type II.Science translational medicine · 2026Article
261 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 2 countries.
Nan LiuCancer and Blood Disorders Center, Dana Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Victoria V HargreavesCancer and Blood Disorders Center, Dana Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Qian ZhuDepartment of Biostatistics and Computational Biology, Dana Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Jesse V KurlandDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jiyoung HongCancer and Blood Disorders Center, Dana Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Woojin KimCancer and Blood Disorders Center, Dana Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Falak SherCancer and Blood Disorders Center, Dana Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Claudio Macias-TrevinoCancer and Blood Disorders Center, Dana Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Julia M RogersDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Committee on Higher Degrees in Biophysics, Harvard University, Cambridge, MA, USA.
Ryo KuritaCell Engineering Division, RIKEN Bioresource Center, Tsukuba, Japan.
Yukio NakamuraCell Engineering Division, RIKEN Bioresource Center, Tsukuba, Japan.
Guo-Cheng YuanDepartment of Biostatistics and Computational Biology, Dana Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Daniel E BauerCancer and Blood Disorders Center, Dana Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Jian XuChildren's Medical Center Research Institute, Department of Pediatrics, University of Texas at Southwestern Medical Center, Dallas, TX, USA.
Martha L BulykDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Committee on Higher Degrees in Biophysics, Harvard University, Cambridge, MA, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Stuart H OrkinCancer and Blood Disorders Center, Dana Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Howard Hughes Medical Institute, Boston, MA, USA. Electronic address: stuart_orkin@dfci.harvard.edu.
Dana-Farber Cancer Institute · USBoston Children's Hospital · USBrigham and Women's Hospital · USDana-Farber/Boston Children's Cancer and Blood Disorders Center · USHarvard University · USRIKEN BioResource Research Center · JPThe University of Texas Southwestern Medical Center · US
Funding
TRANSCRIPTION FACTOR GATA-1 IN TERMINAL ERYTHROID DEVELOPMENTP01HL032262 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI ZON, LEONARD IRA · 1985 to 2021
$38.9MTraining Program in Bioinformatics and Integrative GenomicsT32HG002295 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Peter J Park · 2001 to 2026
$15.8MStem Cell and Transplantation BiologyU54DK106829 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DEREK L STIREWALT · 2015 to 2026
$9.1MMOLECULAR ANALYSIS OF NORMAL AND TYHALASSEMIC DNAR01HL032259 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI ORKIN, STUART H · 1985 to 2022
$8.8MUniversal, Compact Combinatorial Microarrays for DNA Binding Site DiscoveryR01HG003985 · NHGRI · BRIGHAM AND WOMEN'S HOSPITAL · PI BULYK, MARTHA L · 2006 to 2017
$4.9MMolecular Analysis of Transcriptional Enhancers in HematopoiesisR01DK111430 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Jian Xu · 2016 to 2026
$4.8MSystems Biology Analysis of Human ErythropoiesisR01HL119099 · NHLBI · DANA-FARBER CANCER INST · PI ORKIN, STUART H, YUAN, GUO-CHENG · 2014 to 2018
$3.4MA systems biology approach for dissecting enhancer hierarchyR01HG009663 · NHGRI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI YUAN, GUO-CHENG · 2017 to 2020
$2.8MMechanistic roles of BCL11A in globin switching and fetal hemoglobin silencingK01DK093543 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI XU, JIAN · 2011 to 2015
$732kIdentification of sequences and factors required for HbF repressionR03DK109232 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI BAUER, DANIEL EVAN · 2016 to 2017
$226kCharacterizing the role of BCL11A in hematopoietic development and functionsR03DK101665 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI XU, JIAN · 2014 to 2015
$165kHoward Hughes Medical InstituteNHGRI NIH HHS R01 HG003985NHGRI NIH HHS R01 HG009663NHGRI NIH HHS T32 HG002295NHLBI NIH HHS P01 HL032262NHLBI NIH HHS R01 HL032259NHLBI NIH HHS R01 HL119099NIDDK NIH HHS K01 DK093543NIDDK NIH HHS R01 DK111430NIDDK NIH HHS R03 DK101665NIDDK NIH HHS R03 DK109232NIDDK NIH HHS U54 DK106829
Abstract
Fetal hemoglobin (HbF, α
Indexed as
Base Sequencebeta-Globinsbeta-ThalassemiaBinding SitesCarrier ProteinsCell LineChromatinClustered Regularly Interspaced Short Palindromic RepeatsErythroid CellsFetal Hemoglobingamma-GlobinsGene EditingHumansNuclear ProteinsPromoter Regions, GeneticProtein IsoformsBCL11A protein, humanbeta-GlobinsCarrier ProteinsChromatinFetal Hemoglobingamma-GlobinsNuclear ProteinsProtein IsoformsRepressor ProteinsBCL11ACUT&RUNdigital genomic footprintingDNA bindinggene editinghemoglobinprotein-binding microarrayrepressionzinc finger
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.